Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631. 2017

Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
Discovery Research, Mochida Pharmaceutical Co., Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412-8524, Japan. Electronic address: shunsuke.maehara@mochida.co.jp.

Recently, we identified a novel phosphodiesterase 2A (PDE2A) inhibitor, PDM-631 ((S)-3-cyclopropyl-6-methyl-1-(1-(4-(trifluoromethoxy)phenyl)propan-2-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one). PDM-631 showed potent inhibitory activities for human and rat PDE2A with IC50 values of 1.5 and 4.2nM, respectively and more than 2000-fold selectivity against other phosphodiesterases. In rat studies, PDM-631 showed oral bioavailability and good brain penetration, and increased the cGMP levels in the cortex. These data indicate that PDM-631 is a potent, selective, orally active, and brain-penetrable PDE2A inhibitor. In behavioral studies using rat models, PDM-631 (3-30mg/kg) resulted in better discrimination between a novel object and a familiar one 48h after the acquisition phase in the novel object recognition test, thus indicating that PDM-631 increased object recognition memory. In contrast, PDM-631 did not attenuate the conditioned avoidance response at the same dose range (3-30mg/kg) in rats, indicating that PDM-631 did not show an antipsychotic-like effect. In test for extrapyramidal side effect, PDM-631 had no effect on catalepsy at the effective doses (10 and 30mg/kg) in the novel object recognition test, while haloperidol caused catalepsy at a dose of 3mg/kg. Our results suggest that PDM-631 is a good pharmacological tool that can be used to investigate the role of PDE2A and may have therapeutic potential for the treatment of cognitive impairments associated with schizophrenia and neurodegenerative disorders, without any extrapyramidal side effects.

UI MeSH Term Description Entries
D008297 Male Males
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003213 Conditioning, Psychological Simple form of learning involving the formation, strengthening, or weakening of an association between a stimulus and a response. Conditioning, Psychology,Psychological Conditioning,Social Learning Theory,Social Learning Theories,Theory, Social Learning
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001362 Avoidance Learning A response to a cue that is instrumental in avoiding a noxious experience. Aversion Behavior,Aversion Learning,Aversive Behavior,Aversive Learning,Avoidance Behavior,Aversion Behaviors,Aversive Behaviors,Avoidance Behaviors,Behavior, Aversion,Behavior, Aversive,Behavior, Avoidance,Behaviors, Aversion,Behaviors, Aversive,Behaviors, Avoidance,Learning, Aversion,Learning, Aversive,Learning, Avoidance
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
June 2002, Bioorganic & medicinal chemistry letters,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
March 2010, European journal of pharmacology,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
June 2020, Neuropsychopharmacology reports,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
April 2010, International immunopharmacology,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
November 2011, Journal of medicinal chemistry,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
June 2002, Bioorganic & medicinal chemistry letters,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
August 2013, Endocrine research,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
April 2004, Bioorganic & medicinal chemistry,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
May 2014, Journal of medicinal chemistry,
Shunsuke Maehara, and Keita Arakawa, and Kotaro Hoshida, and Hiroshi Nagasue, and Noboru Chida, and Kazunari Nakao, and Shoji Furusako
July 2015, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!